ResearcherNational Institutes for Quantum Science and TechnologyNo recent work listed
Yukie Yoshii
Matched on ORCID iD 0000-0002-1773-5957; OpenAlex author ID A5101462457. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers
Papers 7
- In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against… Last author DOI 10.3390/ijms23105807↗
- Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET. Last author DOI 10.3390/pharmaceutics14091928↗
- Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreat… First author DOI 10.1097/mnm.0000000000001442↗
- Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenog… Last author DOI 10.3390/ph14100950↗
- Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomogra… Last author DOI 10.3390/pharmaceutics14010067↗
- Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer. Co-author DOI 10.1038/s41598-020-61056-5↗
- 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer. Co-author DOI 10.2967/jnumed.118.225045↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hiroki Matsumoto · 7 shared papers, 2019–2022 · strength 0.78
- Paper Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early … DOI 10.3390/pharmaceutics14091928↗
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreat… DOI 10.3390/pharmaceutics14010067↗
- Tatsuya Higashi · 7 shared papers, 2019–2022 · strength 0.78
- Paper Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early … DOI 10.3390/pharmaceutics14091928↗
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreat… DOI 10.3390/pharmaceutics14010067↗
- Fukiko Hihara · 6 shared papers, 2020–2022 · strength 0.68
- Paper Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early … DOI 10.3390/pharmaceutics14091928↗
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreat… DOI 10.3390/pharmaceutics14010067↗
- Chika Igarashi · 6 shared papers, 2020–2022 · strength 0.68
- Paper Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early … DOI 10.3390/pharmaceutics14091928↗
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreat… DOI 10.3390/pharmaceutics14010067↗
- Makoto Ueno · 4 shared papers, 2021–2022 · strength 0.48
- Paper Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early … DOI 10.3390/pharmaceutics14091928↗
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreat… DOI 10.3390/pharmaceutics14010067↗
- Aya Sugyo · 4 shared papers, 2019–2022 · strength 0.42
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xeno… DOI 10.1097/mnm.0000000000001442↗
- Paper 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical M… DOI 10.2967/jnumed.118.225045↗
- Mitsuyoshi Yoshimoto · 4 shared papers, 2019–2022 · strength 0.42
- Paper In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-In… DOI 10.3390/ijms23105807↗
- Paper Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xeno… DOI 10.1097/mnm.0000000000001442↗
- Paper 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical M… DOI 10.2967/jnumed.118.225045↗
- Tadashi Watabe · 1 shared paper, 2021 · strength 0.10
- Jun Hatazawa · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.